Methods and compositions for treating chronic disorders using optically pure (+)-bupropion
US6458374B1 · kind B1 · utility
112Cited by
42References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 28, 1999 |
| Grant date | Oct 1, 2002 |
| Priority date | — |
| Expiry date | Jan 28, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2018
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and compositions are disclosed utilizing the optically pure (+)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.